Merck Signs Licensing Deals for New Experimental HIV Pill
Merck announced seven licensing agreements with generic drug manufacturers to expand access to its experimental HIV pill, alimatravir, in low- and middle-income countries. The partnerships include Viatris as well as three companies from sub-Saharan Africa, such as Aspen Pharmacare Holdings. The move aims to increase availability of the potential new treatment for people living with HIV who may not have access to current therapies due to cost or supply constraints. Merck has been developing alimatravir as a long-acting injectable therapy that could simplify HIV management by reducing dosing frequency compared to daily oral regimens. The licensing strategy aligns with broader efforts in the pharmaceutical industry to address global health disparities and expand access to innovative treatments for underserved populations.
Topics: generic drugs global health HIV licensing agreements